Sale disclosed
Blake Borgeson
Director
Class A Common Stock
- Reported value
- $242K
- Reported price
- $4.84 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
RECURSION PHARMACEUTICALS, INC.
Last 30 daysNo qualifying insider buying. Sales: $445.82K by 3 insiders.
Showing the first 6 of 17 trades on this page.
Director
Class A Common Stock
Director
Class A Common Stock
CEO and President
Class A Common Stock
Director
Class A Common Stock
Director
Class A Common Stock
Director
Class A Common Stock
Director
Class A Common Stock
Director
Class A Common Stock
CEO and President
Class A Common Stock
Director
Class A Common Stock
Director
Class A Common Stock
Director
Class A Common Stock
Director
Class A Common Stock
Director
Class A Common Stock
Director
Class A Common Stock
Director
Class A Common Stock
Director
Class A Common Stock
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Director | Class A Common StockSale10b5-1 | 50,000$4.84 / share | $242K | Oct 6Filed Oct 7 · 1d later | SEC filing |
| Director | Class A Common StockSale10b5-1 | 25,000$5.00 / share | $125K | Oct 6Filed Oct 7 · 1d later | SEC filing |
| CEO and President | Class A Common StockSale10b5-1 | 22,408$3.52 / share | $78.82K | Sep 8Filed Sep 10 · 2d later | SEC filing |
| Director | Class A Common StockSale10b5-1 | 30,000$3.34 / share | $100.2K | Sep 1Filed Sep 2 · 1d later | SEC filing |
| Director | Class A Common StockSale10b5-1 | 30,000$3.25 / share | $97.5K | Aug 4Filed Aug 6 · 2d later | SEC filing |
| Director | Class A Common StockSale10b5-1 | 40,000$3.96 / share | $158.5K | Jul 7Filed Jul 9 · 2d later | SEC filing |
| Director | Class A Common StockSale10b5-1 | 3,963$3.18 / share | $12.6K | Jun 18Filed Jun 22 · 4d later | SEC filing |
| Director | Class A Common StockSale10b5-1 | 40,000$3.62 / share | $144.8K | Jun 5Filed Jun 5 · 0d later | SEC filing |
| CEO and President | Class A Common StockSale10b5-1 | 23,588$3.58 / share | $84.46K | Jun 5Filed Jun 5 · 0d later | SEC filing |
| Director | Class A Common StockSale10b5-1 | 4,386$3.54 / share | $15.53K | Jun 3Filed Jun 4 · 1d later | SEC filing |
| Director | Class A Common StockSale10b5-1 | 30,000$3.68 / share | $110.4K | Jun 2Filed Jun 4 · 2d later | SEC filing |
| Director | Class A Common StockSale10b5-1 | 40,000$3.08 / share | $123.2K | May 22Filed May 27 · 5d later | SEC filing |
| Director | Class A Common StockSale10b5-1 | 40,000$3.37 / share | $134.8K | May 7Filed May 8 · 1d later | SEC filing |
| Director | Class A Common StockSale10b5-1 | 30,000$3.52 / share | $105.6K | May 5Filed May 7 · 2d later | SEC filing |
| Director | Class A Common StockSale10b5-1 | 40,000$3.61 / share | $144.4K | Apr 22Filed Apr 24 · 2d later | SEC filing |
| Director | Class A Common StockSale10b5-1 | 40,000$3.10 / share | $124K | Apr 7Filed Apr 8 · 1d later | SEC filing |
| Director | Class A Common StockSale10b5-1 | 30,000$3.10 / share | $93K | Apr 7Filed Apr 8 · 1d later | SEC filing |
This reflects the filings imported so far, not a complete trading history.
No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.